Headache & Pain

Filter Your Results




First Patient Enrolled in Study of Oral CGRP Receptor Antagonist for Migraine

Tuesday, November 20, 2018—The first patient is enrolled in a phase 3 trial for the oral calcitonin gene-related peptide (CGRP) receptor antagonist rimegepant (Biohaven; New Haven, CT). The trial will a…

New Drug Application for Migraine Headache Therapy Lasmitidan

Monday, November 19, 2018—A New Drug Application (NDA) for lasmiditan (Eli Lilly and Company, Indianapolis, IN) has been submitted to the Food and Drug Administration (FDA). Lasmitidan is an investigat…

Migraines that Affect Vision May Increase Risk of Atrial Fibrillation

Thursday, November 15, 2018—People who experience migraine with visual aura may have an increased risk of atrial fibrillation (AFib), according to a study published in Neurology.  Participan…

Study Confirms Benefits of Laser Interstitial Thermal Therapy

Wednesday, November 14, 2018—A prospective, multi-center clinical study of 42 patients with brain lesions that recurred after stereotactic radiosurgery (SRS) for metastatic brain tumors showed p…

Personal Pain Management App Approved for Use with Intrathecal Drug Delivery Pump

Wednesday, October 24, 2018—The US Food and Drug Administration (FDA) has approved use of an application (myPTM Personal Therapy Manager; Medtronic, Dublin, Ireland) for patients with chronic pain to use…

First Patient Treated in Trial of BHV-3500—A Nasally Delivered CGRP-Receptor Antagonist Being Investigated for Migraine

Tuesday, October 23, 2018—The first participant has been treated in a clinical trial of BHV-3500 (Biohaven, New Haven, CT) for the treatment of patients with migraine. The first intranasal formulation …

Medtronic Launches Control Workflow—An Evidence-Based Protocol for Use With Intrathecal Drug Delivery Pump for Effective Pain Relief

Friday, October 19, 2018—The Control Workflow system (Medtronic, Dublin, Ireland) is an evidence-based approach for use with the intrathecal drug delivery pump (SynchroMed II; Medtronic) to assist phy…

Safety Confirmed for Ubrogepant—A Small-Molecule Oral CGRP Receptor Antagonist for Treatment of Acute Migraine

Wednesday, October 17, 2018—Safety and tolerability studies have been completed for ubrogepant (Allergan, Dublin, Ireland) in patients with acute migraine over 1 year (NCT2867709) and in healthy voluntee…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.